Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05001880 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.
MinorInterventions modifiedEligibility criteria expanded, about 43 words · Secondary endpoints: details revised at 2 of 6 entries · Study description revised · 1 moreShow 4 more changesShow less
Eligibility criteria expanded, about 43 words
Secondary endpoints: details revised at 2 of 6 entries
Study description revised
Site details revised at 2 of 40 sites
NotablePrimary and study completion pushed from Aug 20, 2026 to Aug 1, 2027Site details revised at 1 of 40 sitesv129Show 1 more changeShow less
Minor2 versionsRe-verified since Feb 14, 2025, no change to tracked fieldsv83-v84
MinorStudy Status, Oversight, Study Description, Arms and Interventions, Outcome Measures, Eligibilityv82
Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase II trial compares the usual treatment alone (carboplatin, pemetrexed, and bevacizumab) to using immunotherapy (atezolizumab) plus the usual treatment in treating patients with peritoneal mesothelioma. The usual treatment consists of surgery or chemotherapy. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Pemetrexed is in a class of medications called antifolate antineoplastic agents. It works by stopping cells from using folic acid to make deoxyribonucleic acid and may kill cancer cells. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving atezolizumab with usual treatment may work better than usual treatment alone.